You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
By extending Terra to the Microsoft Azure cloud, the Broad and Verily Life Sciences hope to facilitate better data sharing, analysis, and reuse.
A new partnership between Microsoft, the Broad, and Verily Life Sciences aims to improve collaboration among Terra users worldwide.
The Dutch bioinformatics firm's ImmunoGenomiX technology platform is helping researchers develop therapies for COVID-19 as well as for cancer.
NHGRI has moved the Genotype-Tissue Expression dataset entirely to the cloud in an effort to democratize access to the huge but formerly pricey compendium.
By chopping RNA-seq reads into smaller bits, UW-Tacoma data scientists are able to cut the alignment step to one minute, but the approach has skeptics.
The single-molecule sequencing firm is skipping a beta testing program for its new sequencer, which should be available by the end of the year.
The integration on the Microsoft Azure cloud is helping Kaiser make its vast genomics dataset available to a wider pool of researchers.
Genomic data analytics firm Sentieon uses the challenges to prove and increase customer confidence in its bioinformatics technology.
Researchers from startup Duality Technologies and Dana-Farber have demonstrated the efficacy and speed of a highly secure technique for analyzing encrypted genomic data.
The test detects SARS-CoV-2 from nasopharyngeal swab specimens and runs on standard qPCR instruments, including Thermo Fisher's Applied Biosystems 7500 Fast machine.
Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.
According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.
In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.
Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.